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L-gulono-γ-lactone oxidase (Gulo) is an essential enzyme in the 
synthesis of ascorbic acid from glucose. It is known that gulo is mutated in 
humans and certain primates. Gulo (-/-) mice are a useful animal model of 
human scurvy when they are raised under an ascorbic acid-deficient condition, 
since Gulo (-/-) mice have a defect in the expression of the gulo gene. Based 
on previous findings on bone abnormalities, including multiple chondrocostal 
junction fractures in Gulo (-/-) mice upon ascorbic acid insufficiency, the 
specific factors at work are investigated on the present study. At 4 weeks after 
ascorbic acid withdrawal, a definite loss of weight was found in ascorbic acid-
insufficient Gulo (-/-) mice. Interestingly, the plasma level of osteocalcin, 
which is secreted solely by osteoblasts and is thought to play a role in the 
metabolic regulation of bone, was dramatically decreased in ascorbic acid-
insufficient Gulo (-/-) mice 3 weeks after ascorbic acid withdrawal. In 
addition, it was no longer detected at 4 weeks after ascorbic acid withdrawal. 
The tibia weight of the ascorbic acid-sufficient Gulo (-/-) mice was 
significantly higher than the other three groups. The trabecular bone volume 
was decreased near the growth plate. Moreover, we found a significant 
decrease in the trabecular bone attachment to the growth plate in ascorbic 
acid-insufficient Gulo (-/-) mice at 3 or 4 weeks after ascorbic acid 
withdrawal. Taken together, there are severe defects in normal bone formation 
as the result of ascorbic acid insufficiency, and this effect is closely related to 
a decrease in the osteocalcin level. 
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Scurvy is associated with certain connective tissue symptoms, such 
as vascular purpura, bleeding and gum abnormalities (1). It is caused by 
severe ascorbic acid-deficiency, because ascorbic acid is essential for the 
normal synthesis of collagen (2). When it is considered that the organic bone 
matrix is mainly composed of Type I collagen (3), ascorbic acid-deficiency 
might have a role in bone abnormalities. An inhibition of new bone formation 
after bone grafting and a delay in bone regeneration after injury have been 
observed in scorbutic guinea pigs (4, 5). In human beings, ascorbic acid-
deficiency also causes bone abnormalities such as microfracture, osteolysis 
and osteoporosis (6-8). However, not only deficiency, but also 
supplementation with mega-dose ascorbic acid might exert an effect on bone. 
Indeed, epidemiologic studies were recently reported that suggested a 
supplementation with ascorbic acid may enhance bone formation and overall 
bone health (9, 10). 
Since ascorbic acid is synthesized from glucose in most animals, 
they do not have to take in ascorbic acid by food. However, human beings 
cannot synthesize ascorbic acid (11). This defect is due to the lack of L-
gulono-γ-lactone oxidase that is an essential enzyme for the synthesis of 
ascorbic acid that converts L-gulono-γ-lactone to L-ascorbic acid (12, 13). 
Therefore, ascorbic acid must be obtained in food in humans. For this reason, 
it is believed that ascorbic acid is a clinically important nutrient. Most 
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experimental animals are able to synthesize large amounts of ascorbic acid by 
themselves. This is a major impediment to the study of the in vivo effect of 
ascorbic acid. Therefore, the Gulo (-/-) mice used in this experiment are 
considered a useful animal model for the investigation of the in vivo effect of 
ascorbic acid. Because these mice have a defect in the gulo gene, they are 
unable to synthesize ascorbic acid. 
Gulo (-/-) mice were originally generated for a study of the effect of 
ascorbic acid on the prevention of atherosclerotic plaque formation upon 
ascorbic acid insufficiency (14). Therefore, Gulo (-/-) mice are a very useful 
model for studying the in vivo consequences of supplementation with ascorbic 
acid. 
In the course of a previous investigation of the general characteristics 
of Gulo (-/-) mice (15), skeletal changes such as chondrocostal junction 
thickening and multiple fractures at 5 weeks after withdrawal of ascorbic acid 
were clearly evident. However, the specific mechanisms  have remained 
largely undetermined. Therefore, we investigated the effect of ascorbic acid 





MATERIALS AND METHODS 
 
Mice 
Gulo (+/-) breeding pairs were obtained from the Mutant Mouse 
Regional Resource Center, MMRRC (University of California, Davis, CA, 
USA). We determined the genotypes of the offspring by PCR as 
recommended in the literature (14). Gulo (-/-) and C57BL/6 wild type (WT) 
mice were maintained in specific pathogen free conditions in the animal 
facility at the Seoul National University College of Medicine. Twelve week 
old mice were used in this experiment and the protocol was reviewed and 
approved by Ethics Committee of the Seoul National University. 
 
Supplementation and withdrawal of ascorbic acid 
Gulo (-/-) mice were supplemented with ascorbic acid (3.3g/L, 
Sigma, St. Louis, MO, USA) in water to maintain the general health of the 
mice for 12 weeks. The mice were divided into three groups. One received 
continuous ascorbic acid supplementation untill the end of the experiment, 
referred to as “ascorbic acid-sufficient Gulo (-/-) mice”. Another underwent a 
stoppage of ascorbic acid supplementation for the last 3 weeks of the 
experiment, referred to as “3 week ascorbic acid-insufficient Gulo (-/-) mice”. 
The last underwent a stoppage of ascorbic acid supplementation for the last 4 
weeks of the experiment, referred to as “4 week ascorbic acid-insufficient 
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Gulo (-/-) mice”. To examine the general physiological changes in Gulo (-/-) 
mice upon ascorbic acid insufficiency, the body weight of each of the mice 
was measured at the beginning and end of the experiment. 
 
Analysis of the biochemical components 
At the end of the experiment, blood was collected from the intra-
orbital plexus with a heparinized capillary tube. Plasma was obtained from 
each collected blood sample by centrifugation at 14,000 rpm for 30 min. The 
plasma levels of calcium, phosphorus and alkaline phosphatase (ALP) were 
measured with a chemistry analyzer (Hitachi 7070, HITACHI Science Systems, 
Ltd., Hitachinaka-shi, Japan). The plasma level of osteocalcin was measured 
with a mouse specific enzyme-linked immunosorbent assay (ELISA) kit 
following the manufacturer’s protocol (Biomedical Technologies, INC., 
Stoughton, MA, USA). 
 
Determination of the tibia dry weight 
Mice were sacrificed by cervical dislocation under ether anesthesia. 
The left was dissected and the surrounding soft tissues were removed. After 
de-fatting with a mixed solution of chloroform/ethanol (2:1) for 24 hours, the 
tibia was flushed out with saline to remove the remnant marrow element. The 
fat free tibia was then dried in an oven at 80℃ over 48 hours. The tibia dry 
weight was measured with a microbalance (AEX-200G, SHIMADZU 




The dissected right tibia was fixed in 4% paraformaldehyde for 24 
hours after removal of the surrounding soft tissues. Decalcification was 
performed with 10% EDTA solution for 5 days. The fixed and decalcified 
tibia was embedded in paraffin and sectioned at 4 ㎛. Paraffin bone sections 
were stained with hematoxylin and eosin (H&E). 
 
Statistical analysis 
Results are presented as the mean ± SD. Differences among the 
groups were tested using the Kruskal–Wallis test and the subsequent 
comparisons of each group were performed with the Mann-Whitney test. Data 
were analyzed using PASW for Windows (Version 18.0, SPSS Inc., Chicago, 
IL, USA). All the statistical outcomes were based on a two-sided test, and a P-







The weight of Gulo(-/-) mice was decreased 4 weeks after ascorbic 
acid withdrawal 
To establish that all of the mice fit the same experimental conditions, 
we first determined the weight of each animal before starting the withdrawal 
of ascorbic acid. As shown in Figure 1A, there was no significant difference 
in body weight. The drinking water for the ascorbic acid-insufficient Gulo (-/-) 
mice was replaced with water that did not contain ascorbic acid. Interestingly, 
we did not find a significant change at 3 weeks after ascorbic acid withdrawal, 
but a definite change was observed at 4 weeks in the ascorbic acid-insufficient 
Gulo (-/-) mice. This suggests that ascorbic acid insufficiency does affect the 
loss of weight. However, it remains to be clarified whether it is accompanied 











Figure 1. The weight of mice at baseline (A) and after ascorbic acid 
withdrawal (B) 
The weight of the mice was measured at baseline and after ascorbic 
acid withdrawal. The weight did not exhibit any significant difference among 
the groups at baseline (A). After ascorbic acid withdrawal in the Gulo (-/-) 
mice, the weight was significantly decreased at 4 weeks compared with that of 
the ascorbic acid-sufficient Gulo (-/-) mice (B). Data are presented as the 
means ± SD, and each group included 5 animals. **p < 0.01. 
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The plasma levels of osteocalcin in Gulo(-/-) mice was decreased 
from 3 weeks after ascorbic acid withdrawal 
To examine the effect of ascorbic acid insufficiency on bone 
metabolism, we measured the plasma levels of calcium, phosphorus, alkaline 
phosphatase and osteocalcin. At the end of the experiment, the plasma levels 
of calcium (Figure 2A) and phosphorus (Figure 2B) did not exhibit any 
significant difference among the groups. The plasma level of alkaline 
phosphatase, known as a non-specific marker of bone formation, was 
relatively higher in the ascorbic acid-sufficient Gulo (-/-) mice, but this was 
not statistically significant (Figure 3A). To examine the effect of ascorbic acid 
on bone formation more precisely, the plasma level of osteocalcin, which 
originates solely from bone, was measured. The plasma level of osteocalcin 
was significantly lower in the 3 week ascorbic acid-insufficient Gulo (-/-) 
mice than the WT and ascorbic acid-sufficient Gulo (-/-) mice (Figure 3B). In 
the 4-week ascorbic acid-insufficient Gulo (-/-) mice, osteocalcin was not 








Figure 2. The plasma levels of calcium (A) and phosphorus (B) after 
ascorbic acid withdrawal 
After ascorbic acid withdrawal in Gulo (-/-) mice for the last 3 or 4 
weeks, the plasma levels of cacium (A) and phosphorus (B) were measured. 
The plasma levels of cacium and phosphorus did not exhibit any significant 
difference among the groups. The data are presented as the means ± SD, and 








Figure 3. The plasma levels of alkaline phosphatase (A) and osteocalcin 
(B) after ascorbic acid withdrawal 
After ascorbic acid withdrawal in Gulo (-/-) mice for 3 or 4 weeks, 
the plasma levels of alkaline phosphatase (A) and osteocalcin (B) were 
measured. The plasma level of alkaline phosphatase was not significantly 
different among the groups (A). The plasma level of osteocalcin was 
significantly lower in the 3-week ascorbic acid-insufficient Gulo (-/-) mice 
than those in the WT and ascorbic acid-sufficient Gulo (-/-) mice (B). In the 
4-week ascorbic acid-insufficient Gulo (-/-) mice, osteocalcin was not 
detected in the plasma. Data are presented as the means ± SD, ND = not 
detected, Each group included 5 animals. **p < 0.01.
11 
 
The tibia dry weight of the ascorbic acid-sufficient Gulo (-/-) mice 
was higher than in the other groups 
To examine the total net effect of ascorbic acid-deficiency on bone 
metabolism during the experiment, tibia dry weight was measured after 
ascorbic acid withdrawal in the Gulo (-/-) mice for 3 or 4 weeks (Figure 4A). 
The tibia dry weight of the ascorbic acid-sufficient Gulo (-/-) mice was 
significantly higher than that in the other three groups. However, significant 
differences were not observed among the WT, 3-week and 4-week ascorbic 
acid-insufficient Gulo (-/-) mice. To adjust for the effect of general growth 
difference, the ratio of the tibia weight to final body weight was compared 
between the WT and ascorbic acid-sufficient Gulo (-/-) mice. The ratio was 
significantly higher in the ascorbic acid-sufficient Gulo (-/-) mice than the 









Figure 4. Tibia dry weight and the ratio of the tibia weight to the final 
body weight at the end of the experiment 
After ascorbic acid withdrawal in the Gulo (-/-) mice for the last 3 or 
4 weeks, the tibia dry weight was measured (A). The tibia dry weight in the 
ascorbic acid-sufficient Gulo (-/-) mice was significantly higher than the other 
three groups. The ratio of the tibia weight to the final body weight was 
significantly higher in the ascorbic acid-sufficient Gulo (-/-) mice than the 
WT (B). Data are shown as the means ± SD, Each group included 5 animals. 
*p < 0.05, **p < 0.01.
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The trabecular bone volume in the Gulo (-/-) mice was decreased near  
the growth plate starting at 3 weeks after ascorbic acid withdrawal 
To examine the alteration in the bone architecture after ascorbic acid 
withdrawal, histologic examination was performed. The growth plate of the 
tibia was observed in all four groups, which shows that bony growth was not 
completed at that age (Figure 5). In the metaphysis, the trabecular bone was 
well organized in both the WT and ascorbic acid-sufficient Gulo (-/-) mice 
(Figure 5 A, B). In these two groups, trabecular bone was well attached to the 
growth plate (Figure 5 E, F). In the 3 and 4 week ascorbic acid-insufficient 
Gulo (-/-) mice, the trabecular bone volume was decreased near the growth 
plate (Figure 5 E, F), and there was a significant decrease in the trabecular 
bone attachment to the growth plate (Figure 5 G, H). These findings show that 





Figure 5. The proximal metaphysis and growth plate of the proximal tibia 
after ascorbic acid withdrawal 
After ascorbic acid withdrawal in Gulo (-/-) mice for 3 or 4 weeks, 
the mouse tibia was harvested, fixed, decalcified, sectioned at 4 ㎛ and 
stained with H&E. Compared with the WT (A, E) and ascorbic acid-sufficient 
Gulo (-/-) mice (B, F), in the 3 week (C, G) and 4 week (D, H) ascorbic acid-
insufficient Gulo (-/-) mice the trabecular bone volume was decreased near 
the growth plate, and there was a significant decrease in trabecular bone 




It is well-known that ascorbic acid is a major co-factor for collagen 
synthesis. It is reported that various abnormalities in supporting tissues, such 
as scurvy and chondrocostal fracture, occur under a condition of ascorbic acid 
insufficiency (1, 16). The extensive physiological changes that occur in 
humans with ascorbic acid insufficiency are also reported in Gulo (-/-) mice. 
For example, decreased total cholesterol and high density lipoproteins (HDL), 
but increased low density lipoproteins (LDL) are found in both these mice and 
humans. A prominent decrease of catecholamine production is also reported. 
All of these developments are accompanied by a loss of weight (14). There 
are several reports on the role of ascorbic acid in the generation and 
maintenance of bone in animals under ascorbic acid-insufficient conditions. 
The osteogenic disorder shionogi (ODS) rat is unable to synthesize ascorbic 
acid due to the lack of L-gulono-γ-lactone oxidase, like humans and Gulo (-/-) 
mice. When ascorbic acid is insufficiently supplied to these rats, there is a 
detachment of osteoblasts, characterized by a round-shaped rough 
endoplasmic reticulum (rER), from bone surfaces due to the accumulation of 
malformed collagens inside the rER (17). In the bone of ascorbic acid 
insufficient guinea pigs, there was a remarkable reduction of hydroxyproline 
content and osteocalcin mRNA expression (18, 19). Moreover, decreases in 
the enzymatic activity of alkaline phosphatase in the bone and serum were 
also observed in ascorbic acid insufficient guinea pigs (19). It is generally 
known that spontaneous fracture occurs in sfx mice, because they cannot 
16 
 
synthesize ascorbic acid due to the deletion of the L-gulono-γ-lactone oxidase 
gene, the same as Gulo (-/-) mice. Interestingly, it is reported that there is a 
severe impairment of the differentiation of osteoblasts in sfx mice (20). Based 
on the several reports described above, ascorbic acid is evidently one of the 
important factors for maintaining the structure and function of bone, but the 
factors and mechanisms which are involved in this process are largely 
unknown. Therefore, we investigated the consequences of ascorbic acid 
insufficiency in Gulo (-/-) mice focusing on bone metabolism. 
As shown in Figure 1, a decrease in body weight in ascorbic acid-
insufficient Gulo (-/-) mice occurred at 4 weeks after ascorbic acid withdrawal. 
However, there was no evident weight change in ascorbic acid-insufficient 
Gulo (-/-) mice at 3 weeks after ascorbic acid withdrawal. This is in 
agreement with our previous report on the time- and organ-specific changes in 
the in vivo ascorbic acid concentration in Gulo (-/-) mice (15). Interestingly, 
there was a remarkable change in the trabecular bone volume near the growth 
plate in ascorbic acid-insufficient Gulo (-/-) mice at 3 weeks after ascorbic 
acid withdrawal, although there was no significant difference in weight. In 
accordance with our findings, similar results were found in ascorbic acid-
deficient guinea pigs (19, 21). There was a definite change in bone volume 
without any evident physiological change observed in ascorbic acid-
insufficient Gulo (-/-) mice at 3 weeks after ascorbic acid withdrawal, so it 




Alkaline phosphatase (ALP) and osteocalcin are representative 
markers of bone formation (22). Since both of these factors are increased by 
the activation of osteoblasts, the plasma levels of ALP and osteocalcin 
directly reflect the changes in bone formation in vivo (22, 23). As expected, 
we found a definite decrease of osteocalcin in the plasma of ascorbic acid-
insufficient Gulo (-/-) mice upon ascorbic acid withdrawal for 3 and 4 weeks 
(Figure 3B), but the plasma concentration of alkaline phosphatase did not 
exhibit any significant changes in Gulo (-/-) mice at either of these timepoints 
after ascorbic acid withdrawal (Figure 3A). This may be due to the presence 
of a liver isoform of ALP in the circulation, since the liver is one of the major 
sources of blood ALP (24). Since ascorbic acid plays an important role in the 
production of various kinds of essential enzymes, especially in the liver, the 
increased ALP levels in the ascorbic acid-supplemented Gulo (-/-) mice 
appears to be the result of the continuous supplementation with ascorbic acid. 
Taken together, an abnormality of bone formation was developed in Gulo (-/-) 
mice upon ascorbic acid insufficiency. However, the underlying mechanisms 
related to the decrease in osteocalcin require further investigation. 
Like the increase in the plasma ALP level that resulted from ascorbic 
acid supplementation, the tibia weight in ascorbic acid-sufficient Gulo (-/-) 
mice was higher than in the WT mice and ascorbic acid-insufficient Gulo (-/-) 
mice (Figure 4A). In particular, the relative ratio of the gross weight of the 
tibia against the final body weight was also significantly higher in ascorbic 
acid-sufficient Gulo (-/-) mice than in the WT (Figure 4B). Although this was 
not statistically significant, there was a trend to an in increase in the plasma 
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osteocalcin level in the Gulo (-/-) mice by the supplementation of ascorbic 
acid. The amount of ascorbic acid used in this experiment was 3.3 g/L. Even 
though this is relatively higher than that spontaneously produced by mice, it 
suggests that sufficient amount or mega-dose uptake of ascorbic acid could 
enhance bone formation and effectively maintain bone health. 
There have been reports that mega-doses of ascorbic acid have an 
enhancing effect on bone health in epidemiologic studies. According to a 
report by Hall et al., a positive association was found in postmenopausal 
estrogen/progestin trials between ascorbic acid intake and the BMD (bone 
mineral density) of the spine and hip (9). Interestingly, it is also reported that 
higher total ascorbic acid intake was associated with a reduction of femoral 
neck and trochanter BMD loss in men who had low calcium or low vitamin E 
intake (10). In addition, the femoral neck BMD in male nonsmokers is 
reportedly positively correlated with total ascorbic acid intake (10). However, 
there are other reports that did not find any positive correlation between 
ascorbic acid and bone health (25, 26). Therefore, further studies are required. 
Moreover, the evaluation of ascorbic acid levels in bone after either a 
sufficient amount or mega-dose is also needed. 
Well organized trabecular bone was observed in WT mice and 
ascorbic acid-sufficient Gulo (-/-) mice (Figure 5 A, B). In addition, there was 
intact attachment of trabecular bone to the growth plate (Figure 5 E, F). The 
most striking findings in the ascorbic acid-insufficient Gulo (-/-) mice were 
the reduction of trabecular bone in the proximal metaphysis near the growth 
plate as well as just a small amount of trabecular bone attachment to the 
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growth plate (Figure 5 C, D, G, H). Since the area just distal of the growth 
plate is the most active site for new bone formation, it is thought that this is 
the reason that the reduction in the trabecular bone in the proximal metaphysis 
near the growth plate was more definitely observed than at any other site. 
Based on the previous reports of the trabecular bone reduction in ascorbic acid 
insufficient animal models (16, 21, 27), it is expected that other bony 
abnormalities, such as cortical bone thinning, growth plate reduction and 
malalignment would occur after a longer period of ascorbic acid withdrawal 
than was employed in this experiment. 
In the present study, ascorbic acid-insufficient Gulo(-/-) mice 
exhibited low plasma osteocalcin levels and a definite reduction of trabecular 
bone in the proximal metaphysis near the growth plate. Moreover, all of these 
changes in bone metabolism and structure were not observed upon 
supplementation with a sufficient amount of ascorbic acid. Therefore, these 
findings suggest that the bone formation defect which occurs in cases of 
ascorbic acid-deficiency can be prevented with ascorbic acid supplementation. 
In addition, an enhancement of bone formation as well as the maintenance of 
bone health may be feasible with ascorbic acid supplementation.  Further 
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L-gulono-γ-lactone 산화효소(Gulo)는 포도당으로부터 
아스코르빈산을 합성하는데 있어서 필수적인 효소이다. 사람과 몇몇 
유인원에서는 gulo 유전자의 변이가 있는데, 그로 인해 이들은 
아스코르빈산을 체내에서 합성하지 못한다. Gulo (-/-) 생쥐는 사람과 
같이 gulo 유전자의 발현에 결핍이 있기 때문에, 아스코르빈산을 
결핍시킨 상태에서 키울 경우에 사람 괴혈병에 대해 연구하는데 
유용한 동물 모델로 이용된다. 본 연구팀은 이전 연구에서 다발성 
늑골연골 접합부 골절과 같은 뼈의 이상이 아스코르빈산을 
결핍시킨 Gulo (-/-) 생쥐에서 발생하는 것을 관찰하였다. 이를 
바탕으로 본 연구에서는 아스코르빈산의 결핍이 Gulo (-/-) 생쥐의 뼈 
대사에 미치는 영향 및 관련 인자에 대해 분석하였다. 
아스코르빈산의 공급을 중단하고 4 주 째가 되자 아스코르빈산을 
결핍시킨 Gulo (-/-) 생쥐에서 분명한 체중의 감소가 관찰되었다. 
흥미롭게도 뼈의 대사를 조절하고 골모세포에 의해서만 분비되는 
오스테오칼신의 혈장내 농도가 아스코르빈산의 공급을 중단한지 
3 주 째에 Gulo (-/-) 생쥐에서 급격히 감소하였고, 4 주 째에는 
오스테오칼신이 검출되지 않았다. 경골의 무게는 아스코르빈산을 
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충분히 공급하여준 Gulo (-/-) 생쥐에서 다른 3 군보다 더 나갔다. 
아스코르빈산을 결핍시킨 후 3 주와 4 주 차의 Gulo (-/-) 생쥐에서는 
성장판 근처에서 해면골의 양이 감소되어 있었고 해면골과 
성장판과의 부착이 감소되어 있었다. 이상의 소견은 아스코르빈산의 
결핍은 정상적인 뼈의 생성에 심각한 장애를 일으키며, 이는 
오스테오칼신 농도의 감소와 밀접하게 연관되어있음을 시사한다. 
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